P 7170

Drug Profile

P 7170

Alternative Names: P7170

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Piramal Healthcare
  • Developer Piramal Enterprises
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Activin receptor antagonists; DNA activated protein kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammation; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in India (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in India (PO, Capsule)
  • 09 Aug 2012 Piramal Healthcare plans a phase I trial for Solid tumours in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top